Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of ...

With current treatments and vaccines for H5N1 considered insufficient or poorly matched to circulating strains, Arcturus' sa-mRNA approach could offer a more effective solution. However ...

While drugmakers are hard at work on the shots, they’re not yet ready to blunt the impact of a potential pandemic.

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Arcturus Therapeutics ARCT in the last three months. The table below summarizes their recent ...

After hours: January 28 at 5:53:48 PM EST ...

The Bluntness Editorial Staff is dedicated to bring you the many stories of cannabis culture - stories that speak to the enthusiast and expert in an unfiltered but factual manner. Everyday, our ...